TMO Pengajuan SEC - Thermo Fisher Scientific Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	HCHV7422L5HDJZCRFL38
CIK	97745

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Thermo Fisher Scientific Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 2, 2025	EX-99.1	Thermo Fisher Scientific Completes Acquisition of Solventum’s Purification and Filtration Business Highly Complementary Technologies Strengthen Thermo Fisher’s Portfolio in Bioprocessing and Adjacent Markets Media Contact Information: Sandy Pound Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 THERMO FISHER S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commi
August 1, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 28, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as
July 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 THERMO FISHER SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commissio
July 23, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commissio
July 23, 2025	EX-99.1	Thermo Fisher Scientific Reports Second Quarter 2025 Results Exhibit 99.1 News Media Contact Information: Sandy Pound Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Second Quarter 2025 Results WALTHAM, Mass. (July 23, 2025) – Thermo Fisher Scientific Inc. (NYSE: TM
June 17, 2025	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (mark one) [ X ] Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2024 [ ] Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC.
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 04-2209186 (State or other jurisdiction UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 168 Third Avenue Waltham, MA 02451 (Address of princi
May 30, 2025	EX-1.01	Exhibit 1.01 Exhibit 1.01 Conflict Minerals Report I. INTRODUCTION Thermo Fisher Scientific Inc. (“Thermo Fisher,” the “Company,” “we,” “us” or “our”) has included this Conflict Minerals Report (the “Report”) as an exhibit to its Form SD, as provided for in Form SD and Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“Rule 13p-1” or the “Conflict Minerals Rule”) for the reporting period from J
May 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 THERMO FISHER SCIENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commission
May 22, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commission
May 22, 2025	EX-10.1	Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of May 21, 2025 Exhibit 10.1 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Marc N. Casper Award date
May 2, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 29, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as
April 23, 2025	EX-99.1	Thermo Fisher Scientific Reports First Quarter 2025 Results Exhibit 99.1 News Media Contact Information: Sandy Pound Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports First Quarter 2025 Results WALTHAM, Mass. (April 23, 2025) – Thermo Fisher Scientific Inc. (NYSE: TM
April 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 THERMO FISHER SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commissi
April 15, 2025	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on April 28, 2025, pursuant to the provisions of Rule 12d2-2 (a).
April 10, 2025	CORRESP	2 Thermo Fisher Scientific 168 Third Avenue Waltham, MA 02451 www.thermofisher.com VIA EDGAR April 10, 2025 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Kristin Lochhead and Michael Fay Division of Corporation Finance Office of Industrial Applications and Services Re: Response to Comment Letter dated April 3, 2025 Thermo Fisher
April 8, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__ ) þ Filed by the Registrant ¨ Filed by a Party other UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6
April 8, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commi
March 3, 2025	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on March 14, 2025, pursuant to the provisions of Rule 12d2-2 (a).
February 25, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commi
February 24, 2025	S-3ASR	As filed with the Securities and Exchange Commission on February 24, 2025 As filed with the Securities and Exchange Commission on February 24, 2025 Registration No.
February 24, 2025	EX-25.3	The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of The Bank of New York Mellon Trust Company, N.A. with respect to the Thermo Fisher International Senior Indenture dated as of August 9, 2016 Exhibit 25.3 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW
February 24, 2025	EX-FILING FEES	Filing Fees Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Thermo Fisher Scientific Inc.
February 24, 2025	EX-25.1	The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of The Bank of New York Mellon Trust Company, N.A. with respect to the Thermo Fisher Senior Indenture dated as of November 20, 2009 Exhibit 25.1 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW
February 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as spec
February 20, 2025	EX-10.55	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 19, 2025 Exhibit 10.55 THERMO FISHER SCIENTIFIC INC. RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Award date (“Award Date”): Number of shares of the Comp
February 20, 2025	EX-10.54	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 19, 2025 Exhibit 10.54 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Award date (“Award Date”)
February 20, 2025	EX-10.57	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 19, 2025 Exhibit 10.57 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Marc N. Casper Award date
February 20, 2025	EX-10.56	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement effective as of February 19, 2025 Exhibit 10.56 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Grant date (“Grant Date”): Number of shares of
February 20, 2025	EX-10.58	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 19, 2025 Exhibit 10.58 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Marc N. Casper Grant date (“Grant Date”): Numb
February 20, 2025	EX-21	Subsidiaries of the Registrant Exhibit 21 THERMO FISHER SCIENTIFIC INC. NAME STATE OR JURISDICTION OF ORGANIZATION 0972792 B.C. LTD Canada 236 Perinton Parkway, LLC New York 27 Forge Parkway LLC Delaware Abgene Inc. Delaware Abgene Limited England ABII 2 Limited England ACI Holdings Inc. New York Acoustic Cytometry Systems, Inc. Delaware AcroMetrix LLC California Acros Organics BV Belgium Acurian, Inc. Delaware Advanced Biotech
February 20, 2025	EX-19	Thermo Fisher Scientific Inc. Insider Trading Policy. Exhibit 19 Policies & Procedures EFFECTIVE DATE: January 1, 2024 Title: INSIDER TRADING POLICY Supersedes: February 26, 2019 Total Pages: 5 POLICY1 Securities laws prohibit anyone who is aware of material non-public information about a company from trading in securities of that company, commonly known as “insider trading”.
February 20, 2025	EX-22	Subsidiary Issuer of Guaranteed Securities Exhibit 22 Subsidiary Issuer of Guaranteed Securities Thermo Fisher Scientific Inc.
February 20, 2025	EX-3.4	Amended and Restated By-Laws of the Registrant, as amended and effective as of February 19, 2025 Exhibit 3.4 As amended and restated effective as of February 19, 2025 Thermo Fisher Scientific Inc. BY-LAWS TABLE OF CONTENTS Title Page ARTICLE I - STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Notice of Meetings 4 Section 4. Quorum; Adjournments 4 Section 5. Voting; Proxies 5 Section 6. Inspectors of Elections 6 Section 7. Presiding Officer and Secretary 6 S
February 19, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commi
January 30, 2025	EX-99.1	Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results WALTHAM, Mass. (January 30, 2025) –
January 30, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commis
November 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 28, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registran
October 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 THERMO FISHER SC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commis
October 23, 2024	EX-99.1	Thermo Fisher Scientific Reports Third Quarter 2024 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Third Quarter 2024 Results WALTHAM, Mass. (October 23, 2024) – Thermo Fisher S
September 12, 2024	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on September 23, 2024, pursuant to the provisions of Rule 12d2-2 (a).
August 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 29, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as
July 24, 2024	EX-99.1	Thermo Fisher Scientific Reports Second Quarter 2024 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Second Quarter 2024 Results WALTHAM, Mass. (July 24, 2024) – Thermo Fisher Sci
July 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 THERMO FISHER SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commissio
July 17, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 20) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
July 10, 2024	EX-99.(A)(5)(W)	Press Release, dated July 10, 2024 (filed as Exhibit (a)(5)(W) to the Registrant's Schedule TO-T/A filed July 10, 2024 File No. 005-93360 and incorporated in this document by reference). Exhibit (a)(5)(W) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 THERMO FISHER SCIEN false000009774500000977452023-10-172023-10-170000097745us-gaap:CommonStockMember2023-10-172023-10-170000097745tmo:Zero875NotesDue2031Member2023-10-172023-10-170000097745tmo:Zero125NotesDue2025Member2023-10-172023-10-170000097745tmo:One500NotesDue2039Member2023-10-172023-10-170000097745tmo:Three650NotesDue2034Member2023-10-172023-10-170000097745tmo:Zero750NotesDue2024Member2023-10-172023-10-1700000
July 10, 2024	EX-99.(A)(5)(X)	Email to Nominees and Other Market Participants Holding Olink Holding AB (publ) Common Shares from DNB Markets, a part of DNB Bank ASA, Sweden Branch, on July 10, 2024. Exhibit (a)(5)(X) Dear Shareholders and Market Participants, Thermo Fisher Scientific has today announced the commencement of a subsequent offering period in order to allow any remaining shareholders accept the offer for the common shares of Olink.
July 10, 2024	EX-99.(A)(1)(I)	Form of Acceptance Form for Shares for the Subsequent Offering Period. Exhibit (a)(1)(I) Acceptance Form for the Subsequent Offering Period by Orion Acquisition AB to shareholders in Olink Holding AB (publ) Shareholders of Common Shares, ISIN: SE0015797568 Please submit this Acceptance form to: DNB Markets, a part of DNB Bank ASA, Sweden Branch Regeringsgatan 59, 105 88 Stockholm, Sweden DNB Markets, Securities Services at emissioner@dnb.
July 10, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 19) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
June 20, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 18) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
June 20, 2024	EX-99.(A)(5)(V)	Press Release issued by Thermo Fisher Scientific Inc., dated June 20, 2024. Exhibit (a)(5)(V) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
June 14, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (mark one) [ X ] Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2023 [ ] Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC.
May 30, 2024	EX-1.01	Exhibit 1.01 Exhibit 1.01 Conflict Minerals Report I. INTRODUCTION Thermo Fisher Scientific Inc. (“Thermo Fisher,” the “Company,” “we,” “us” or “our”) has included this Conflict Minerals Report (the “Report”) as an exhibit to its Form SD, as provided for in Form SD and Rule 13p-1 under the Securities Exchange Act of 1934, as amended (“Rule 13p-1” or the “Conflict Minerals Rule”) for the reporting period from J
May 30, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 (State or other jurisdiction of incorpo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 (State or other jurisdiction of incorporation or organization) (Commission File Number) 168 Third Avenue Waltham, MA 02451 (Address of principal executive offices) (Zip Code) Michael A. Box
May 24, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commission
May 14, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SC TO-T/A 1 scto-ta.htm AMENDMENT NO. 17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 17) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (U
May 14, 2024	EX-99.(A)(5)(U)	Excerpt from transcript of Thermo Fisher Scientific, Inc.’s CEO remarks given on May 14, 2024 at the Bank of America Securities 2024 Health Care Conference. Exhibit (a)(5)(U) The following is an excerpt from the transcript of Thermo Fisher’s CEO remarks given on May 14, 2024 at the Bank of America Securities 2024 Health Care Conference: [W]e're looking forward ﬁrst to ﬁnishing the regulatory process in Olink, and we're on track for the middle of the year. . . . I'm just excited to welcome the colleagues and have that oﬀering for our customers. * * *
May 3, 2024	EX-10.7	Form of Thermo Fisher Scientific Inc.’s Performance Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 21, 2024. Exhibit 10.7 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Marc N. Casper Grant date (“Grant Date”): Numbe
May 3, 2024	EX-10.5	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 21, 2024. Exhibit 10.5 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Marc N. Casper Award date
May 3, 2024	EX-10.4	Form of Thermo Fisher Scientific Inc.’s Performance Nonstatutory Stock Option Agreement effective as of February 21, 2024 Exhibit 10.4 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Grant date (“Grant Date”): Number of shares of
May 3, 2024	EX-10.2	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 21, 2024 Exhibit 10.2 THERMO FISHER SCIENTIFIC INC. RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Award date (“Award Date”): Number of shares of the Compa
May 3, 2024	EX-10.1	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 21, 2024 Exhibit 10.1 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Award date (“Award Date”):
May 3, 2024	EX-10.3	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement effective as of February 21, 2024 Exhibit 10.3 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Grant date (“Grant Date”): Number of shares of
May 3, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as
May 3, 2024	EX-10.6	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 21, 2024. Exhibit 10.6 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Marc N. Casper Grant date (“Grant Date”): Numbe
May 1, 2024	EX-99.(A)(5)(T)	Press Release issued by Thermo Fisher Scientific Inc., dated May 1, 2024. Exhibit (a)(5)(T) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
May 1, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 16) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
April 24, 2024	EX-99.(A)(5)(S)	Excerpt from transcript of Thermo Fisher Scientific, Inc.’s First Quarter 2024 Earnings Call held on April 24, 2024. Exhibit (a)(5)(S) The following is an excerpt from the transcript of Thermo Fisher’s First Quarter Earnings Call held on April 24, 2024: Turning to our planned acquisition of Olink, we’re working through the regulatory process and the transaction is on track to close by mid-2024. We look forward to welcoming our new colleagues to the company later this year. * * *
April 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 THERMO FISHER SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commissi
April 24, 2024	EX-99.1	Thermo Fisher Scientific Reports First Quarter 2024 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports First Quarter 2024 Results WALTHAM, Mass. (April 24, 2024) – Thermo Fisher Sci
April 24, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 15) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
April 9, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__ ) þ Filed by the Registrant ¨ Filed by a Party other UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6
April 9, 2024	DEF 14A	DEF 14A Our Mission is to enable our customers to make the world Notice of Annual Meeting of Shareholders and Proxy Statement 2024Our Mission is to enable our customers to make the world Healthier Cleaner Safer We make a positive impact on human health by providing our customers with advanced technologies and expertise to deliver breakthrough medicines and diagnostics that improve lives worldwide.
April 9, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filedby the Registrant ☐ Filedby a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permi
March 14, 2024	SC 13D/A	LSAQ / LifeSci Acquisition II Corp / Thermo Fisher Scientific Inc. - AMENDMENT NO. 1 Activist Investment SC 13D/A 1 sc13da.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Michael A. Boxer Senior Vice President and General Counsel Thermo Fisher
March 6, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 14) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
March 6, 2024	EX-99.(A)(5)(R)	Excerpt from transcript of Thermo Fisher Scientific, Inc.’s CEO remarks given on March 6, 2024 at the TD Cowen 44th Annual Health Care Conference. Exhibit (a)(5)(R) The following is an excerpt from the transcript of Thermo Fisher’s CEO remarks given on March 6, 2024 at the TD Cowen 44th Annual Health Care Conference: I’m very excited about Olink.
March 1, 2024	EX-99.(A)(5)(Q)	Press Release issued by Thermo Fisher Scientific Inc., dated March 1, 2024. Exhibit (a)(5)(Q) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
March 1, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 13) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
February 22, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as spec
February 22, 2024	EX-3.4	Amended and Restated By-Laws of the Registrant, as amended and effective as of February 21, 2024 Exhibit 3.4 As amended and restated effective as of February 21, 2024 Thermo Fisher Scientific Inc. BY-LAWS TABLE OF CONTENTS Title Page ARTICLE I - STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Notice of Meetings 3 Section 4. Quorum; Adjournments 4 Section 5. Voting; Proxies 4 Section 6. Inspectors of Elections 5 Section 7. Presiding Officer and Secretary 5 S
February 22, 2024	EX-10.49	Thermo Fisher Scientific Inc. Deferred Compensation Plan, Exhibit 10.49 Thermo Fisher Scientific Inc. Deferred Compensation Plan Amended & Restated Effective January 1, 2024 IMPORTANT NOTE This document has not been approved by the Department of Labor, Internal Revenue Service, or any other governmental entity. An adopting Employer must determine whether the Plan is subject to the federal securities laws and the securities laws of the various states. An
February 22, 2024	EX-10.1	Thermo Fisher Scientific Inc. Deferred Compensation Plan for Directors of the Registrant, as amended and restated effective February 21, 2024 Exhibit 10.1 THERMO FISHER SCIENTIFIC INC. DEFERRED COMPENSATION PLAN FOR DIRECTORS, As amended and restated effective as of February 21, 2024 Section 1.Participation. Any director of Thermo Fisher Scientific Inc. (the “Company”) may elect to have such percentage as he or she may specify of the fees otherwise payable to him or her deferred and paid to him or her as provided in this Plan. A directo
February 22, 2024	EX-21	Subsidiaries of the Registrant Exhibit 21 THERMO FISHER SCIENTIFIC INC. NAME STATE OR JURISDICTION OF ORGANIZATION 0972792 B.C. LTD Canada 236 Perinton Parkway, LLC New York 27 Forge Parkway LLC Delaware Abgene Inc. Delaware Abgene Limited England ABII 2 Limited England ACI Holdings Inc. New York Acoustic Cytometry Systems, Inc. Delaware AcroMetrix LLC California Acros Organics BV Belgium Acurian, Inc. Delaware Advanced Biotech
February 22, 2024	EX-97	Clawback Policy Exhibit 97 Policies & Procedures EFFECTIVE DATE: October 2, 2023 Title: CLAWBACK POLICY Supersedes: February 25, 2019 Total Pages: 3 POLICY This Clawback Policy (this “Policy”), relates to the Company’s right to recover compensation previously paid to specified employees in certain circumstances, including the recovery of Erroneously Awarded Compensation (as defined below) in accordance with Section 303A.
February 22, 2024	EX-22	Subsidiary Issuer of Guaranteed Securities Exhibit 22 Subsidiary Issuer of Guaranteed Securities Thermo Fisher Scientific Inc.
February 20, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 12) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
February 13, 2024	SC 13G/A	TMO / Thermo Fisher Scientific Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02069-thermofisherscientif.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Thermo Fisher Scientific Inc Title of Class of Securities: Common Stock CUSIP Number: 883556102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate b
January 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 THERMO FISHER SC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R
January 31, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 11) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
January 31, 2024	EX-99.(A)(5)(P)	Excerpt from transcript of Thermo Fisher Scientific, Inc.’s Fourth Quarter and Full Year 2023 Earnings Call held on January 31, 2024. Exhibit (a)(5)(P) The following is an excerpt from the transcript of Thermo Fisher’s Fourth Quarter and Full Year 2023 earnings call held on January 31, 2024: During the fourth quarter, we announced our intent to acquire Olink, a provider of advanced proteomics solutions that help researchers to gain an understanding of disease at the protein level rapidly and efficiently.
January 31, 2024	EX-99.1	Thermo Fisher Scientific Reports Fourth Quarter 2023 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Fourth Quarter 2023 Results WALTHAM, Mass. (January 31, 2024) – Thermo Fisher
January 4, 2024	EX-99.(A)(5)(O)	Press Release issued by Thermo Fisher Scientific Inc., dated January 4, 2024. Exhibit (a)(5)(O) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
January 4, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 10) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
December 22, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 9) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
December 15, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 8) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
December 15, 2023	EX-99.(A)(5)(N)	Press Release issued by Thermo Fisher Scientific Inc., dated December 15, 2023. Exhibit (a)(5)(N) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
December 12, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 7) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
December 12, 2023	CORRESP	Ting S. Chen Ting S. Chen [email protected] T+1-212-474-1794 New York Bethany Pfalzgraf [email protected] T+1-212-474-1728 New York December 12, 2023 Thermo Fisher Scientific Inc. Olink Holding AB (publ) Schedule TO-T Filed December 1, 2023 Filed by Orion Acquisition AB and Thermo Fisher Scientific Inc. File No. 005-93360 Dear Ms. Chalk and Messrs. Callaghan and Kim: On behalf of Thermo Fisher Scientific
December 5, 2023	EX-1.1	THERMO FISHER SCIENTIFIC INC. 5.000% Senior Notes due 2026 5.000% Senior Notes due 2029 5.200% Senior Notes due 2034 UNDERWRITING AGREEMENT November 28, 2023 BofA Securities, Inc. Morgan Stanley & Co. LLC U.S. Bancorp Investments, Inc. Wells Fargo Se Exhibit 1.1 Execution Copy THERMO FISHER SCIENTIFIC INC. $1,000,000,000 5.000% Senior Notes due 2026 $1,000,000,000 5.000% Senior Notes due 2029 $500,000,000 5.200% Senior Notes due 2034 UNDERWRITING AGREEMENT November 28, 2023 BofA Securities, Inc. Morgan Stanley & Co. LLC U.S. Bancorp Investments, Inc. Wells Fargo Securities, LLC BOFA SECURITIES, INC. MORGAN STANLEY & CO. LLC U.S. Bancorp Invest
December 5, 2023	EX-4.2	Twenty-Eighth Supplemental Indenture, dated as of December 5, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee Exhibit 4.2 EXECUTION VERSION THERMO FISHER SCIENTIFIC INC., as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee TWENTY-EIGHTH SUPPLEMENTAL INDENTURE Dated as of December 5, 2023 5.000% Senior Notes due 2026 5.000% Senior Notes due 2029 5.200% Senior Notes due 2034 THIS TWENTY-EIGHTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) is dated as of December 5, 2023 betwee
December 5, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-08002 04-2209186 (State or other jurisdiction of incorporation) (Commi
December 1, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 5) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 5) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Sh
December 1, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 6) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
December 1, 2023	EX-99.(A)(1)(H)	AMENDED AND RESTATED OFFER TO PURCHASE FOR CASH All Outstanding Common Shares All Outstanding American Depositary Shares, each representing one Common Share, TABLE OF CONTENTS Exhibit (a)(1)(H) AMENDED AND RESTATED OFFER TO PURCHASE FOR CASH All Outstanding Common Shares and All Outstanding American Depositary Shares, each representing one Common Share, of Olink Holding AB (publ) at $26.
December 1, 2023	EX-99.(A)(5)(M)	Press Release issued by Thermo Fisher Scientific Inc., dated December 1, 2023. Exhibit (a)(5)(M) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
November 30, 2023	CORRESP	Ting S. Chen Ting S. Chen [email protected] T+1-212-474-1794 New York Bethany Pfalzgraf [email protected] T+1-212-474-1728 New York November 30, 2023 Thermo Fisher Scientific Inc. Olink Holding AB (publ) Schedule TO-T Filed October 31, 2023 Filed by Orion Acquisition AB and Thermo Fisher Scientific Inc. File No. 005-93360 Dear Ms. Chalk and Messrs. Callaghan and Kim: On behalf of Thermo Fisher Scientific
November 29, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: THERMO FISHER SCIENTIFIC INC.
November 29, 2023	424B5	Thermo Fisher Scientific Inc. $1,000,000,000 5.000% Senior Notes due 2026 $1,000,000,000 5.000% Senior Notes due 2029 $500,000,000 5.200% Senior Notes due 2034 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-263034 PROSPECTUS SUPPLEMENT (To prospectus dated February 25, 2022) $2,500,000,000 Thermo Fisher Scientific Inc. $1,000,000,000 5.000% Senior Notes due 2026 $1,000,000,000 5.000% Senior Notes due 2029 $500,000,000 5.200% Senior Notes due 2034 We are offering $1,000,000,000 aggregate principal amount of 5.000% Senior Notes due 2026
November 28, 2023	FWP	Thermo Fisher Scientific Inc. $1,000,000,000 5.000% Senior Notes due 2026 (the “2026 Notes”) $1,000,000,000 5.000% Senior Notes due 2029 (the “2029 Notes”) $500,000,000 5.200% Senior Notes due 2034 (the “2034 Notes”) November 28, 2023 Pricing Term Sh Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-263034 Thermo Fisher Scientific Inc. $1,000,000,000 5.000% Senior Notes due 2026 (the “2026 Notes”) $1,000,000,000 5.000% Senior Notes due 2029 (the “2029 Notes”) $500,000,000 5.200% Senior Notes due 2034 (the “2034 Notes”) November 28, 2023 Pricing Term Sheet Issuer: Thermo Fisher Scientific Inc. Securities: 5.000% Sen
November 28, 2023	424B5	Subject to Completion, dated November 28, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
November 14, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 4) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
November 13, 2023	EX-99.(A)(5)(L)	Email to former and current Olink Holding AB (publ) employees from Global Shares on November 13, 2023. Exhibit (a)(5)(L) Email to Current and Former Employees with Global Share Accounts: Orion Acquisition AB (“Buyer”), a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc.
November 13, 2023	EX-99.(A)(5)(K)	Message to former and current Olink Holding AB (publ) employees on the employee portal website published by Exhibit (a)(5)(K) Message to Current and Former Employees with Global Share Accounts: Orion Acquisition AB (“Buyer”), a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc.
November 13, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
November 9, 2023	S-8	As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.
November 9, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Thermo Fisher Scientific Inc.
November 9, 2023	EX-99.1	Thermo Fisher Scientific Inc. 401(k) Retirement Plan, as amended Exhibit 99.1 THERMO FISHER SCIENTIFIC INC. 401(K) RETIREMENT PLAN (Amended and Restated Effective January 1, 2017) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01 After-Tax Account 2 Section 1.02 Account 2 Section 1.03 Accounting Date 2 Section 1.04 Before-Tax Account 2 Section 1.05 Beneficiary 2 Section 1.06 Benefits Department 2 Section 1.07 Board 2 Section 1.08 Catch-Up Account 2 Se
November 7, 2023	EX-99.1	TO: Directors and Executive Officers of Thermo Fisher Scientific Inc. Exhibit 99.1 TO: Directors and Executive Officers of Thermo Fisher Scientific Inc. DATE: November 7, 2023 RE: Important Notice of Blackout Period and Regulation BTR Trading Restrictions Federal securities laws require Thermo Fisher Scientific Inc. (“we”, “us”, “our” or the “Company”) to send you a notice whenever restrictions are imposed on your trading in the shares of our common stock, $1.00 par
November 7, 2023	8-K	Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R
November 6, 2023	EX-99.(A)(5)(J)	Email to Nominees and Other Market Participants Holding Olink Holding AB (publ) Common Shares from DNB Markets, a part of DNB Bank ASA, Sweden Branch, on November 6, 2023. Exhibit (a)(5)(J) Dear nominees and other market participants holding Olink Holding AB (publ) common shares, ISIN SE0015797568 Reference is made to the previously announced tender offer (the “Offer”) by Orion Acquisition AB for all the outstanding common shares and ADSs of Olink Holding AB (publ), which was commenced on October 31, 2023.
November 6, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
November 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registran
November 2, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,
November 2, 2023	EX-99.(A)(5)(I)	Website published by DNB Markets, a part of DNB Bank ASA, Sweden Branch, on November 2, 2023. Exhibit (a)(5)(I) Aktuella Transaktioner Public Tender Offer to Shareholders in Olink Holding AB (publ) ThermoFisher-medhvitt Thermo Fisher Scientific commenced on October 31, 2023 a Tender Offer for all shares in Olink Holding AB (publ).
October 31, 2023	EX-99.(A)(1)(A)	OFFER TO PURCHASE FOR CASH All Outstanding Common Shares All Outstanding American Depositary Shares, each representing one Common Share, TABLE OF CONTENTS Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH All Outstanding Common Shares and All Outstanding American Depositary Shares, each representing one Common Share, of Olink Holding AB (publ) at $26.
October 31, 2023	EX-99.(D)(7)	CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit (d)(7) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-99.(D)(10)	RETENTION BONUS AGREEMENT Exhibit (d)(10) RETENTION BONUS AGREEMENT This Retention Bonus Agreement (“Agreement”) is made and entered into as of October , 2023, by and between Thermo Fisher Scientific, Inc.
October 31, 2023	EX-99.(A)(5)(H)	Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink Shareholders to Receive $26.00 per Common Share and ADS in Cash Exhibit (a)(5)(H) FOR IMMEDIATE RELEASE Media Contact Information: Investor Contact Information: Sandy Pound Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.
October 31, 2023	EX-99.(A)(1)(G)	Notice of Offer to Purchase All Outstanding Common Shares and All Outstanding American Depositary Shares, each representing one Common Share, OLINK HOLDING AB (PUBL) $26.00 per Share or ADS, pursuant to the Offer to Purchase, dated October 31, 2023, Exhibit (a)(1)(G) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Offer Securities (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).
October 31, 2023	EX-99.(D)(12)	CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit (d)(12) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33985 AB (U.C.T. ORION ACQUISITION AB) (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common
October 31, 2023	EX-99.(D)(13)	CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit (d)(13) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-99.(D)(6)	CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit (d)(6) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-99.(D)(8)	HIGHLIGHTED EXECUTIVE BENEFITS Exhibit (d)(8) Mr. Carl Raimond Dear Carl Raimond, We are very excited about you joining Thermo Fisher Scientific Inc. following the expected consummation of our acquisition of Olink. This letter is intended to clarify provisions of your employment with us that will only become effective as of the date Olink becomes a wholly-owned subsidiary of Thermo Fisher Scientific Inc., or such earlier
October 31, 2023	EX-99.(D)(11)	CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit (d)(11) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-99.(A)(1)(E)	OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE OLINK HOLDING AB (publ) PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023 GOLDCUP 33985 AB (u.c.t. Orio Exhibit (a)(1)(E) OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE OF OLINK HOLDING AB (publ) PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023 BY GOLDCUP 33985 AB (u.
October 31, 2023	EX-99.(A)(1)(C)	Cash consideration Exhibit (a)(1)(C) Acceptance Form for the public cash tender offer by Goldcup 33985 AB (u.
October 31, 2023	EX-99.(A)(1)(B)	Letter of Transmittal to Tender American Depositary Shares (“ADSs”) (Each Representing 1 Common Share) of OLINK HOLDING AB (PUBL) $26.00 per ADS, in cash, without interest, pursuant to the Offer to Purchase, dated October 31, 2023 GOLDCUP 33985 AB (u Exhibit (a)(1)(B) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
October 31, 2023	EX-99.(D)(9)	NONCOMPETITION AGREEMENT Exhibit (d)(9) NONCOMPETITION AGREEMENT THIS AGREEMENT, dated as of October 15, 2023, is made by and between Carl Raimond (the “Employee”), and Thermo Fisher Scientific Inc.
October 31, 2023	EX-99.(D)(3)	TRANSFER RESTRICTION AGREEMENT Exhibit (d)(3) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-99.(A)(1)(D)	OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE OLINK HOLDING AB (publ) PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023 GOLDCUP 33985 AB (u.c.t. Orio Exhibit (a)(1)(D) OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE OF OLINK HOLDING AB (publ) PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023 BY GOLDCUP 33985 AB (u.
October 31, 2023	EX-99.(D)(4)	June 25, 2023 Exhibit (d)(4) June 25, 2023 CONFIDENTIAL Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451 Ladies and Gentlemen: In connection with proposed discussions between Olink Holding AB (publ) (the “Company”) and Thermo Fisher Scientific Inc. regarding a Company business update (such discussions, the “Business Update”) or the potential consideration by Thermo Fisher Scientific I
October 31, 2023	EX-99.(D)(5)	CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED. Exhibit (d)(5) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-FILING FEES	Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33985 AB (u.c.t. Orion Acquisition AB) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Parent of Offeror Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33985 AB (u.
October 31, 2023	EX-99.(D)(2)	TENDER AND SUPPORT AGREEMENT Exhibit (d)(2) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
October 31, 2023	EX-99.(D)(1)	PURCHASE AGREEMENT THERMO FISHER SCIENTIFIC INC. OLINK HOLDING AB (PUBL), dated as of October 17, 2023 TABLE OF CONTENTS Exhibit (d)(1) PURCHASE AGREEMENT between THERMO FISHER SCIENTIFIC INC.
October 31, 2023	EX-99.(A)(1)(F)	Stockholm, 31 October 2023 Exhibit (a)(1)(F) Stockholm, 31 October 2023 Dear Shareholders, nominee banks and other market participants holding shares in Olink Holding AB (publ) (“Olink”), Thermo Fisher Scientific Inc.
October 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 THERMO FISHER SC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R
October 25, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) American Depositary Shares, each representing one Common Share, quota value SEK 2.
October 25, 2023	EX-99.1	Thermo Fisher Scientific Reports Third Quarter 2023 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Third Quarter 2023 Results WALTHAM, Mass. (October 25, 2023) – Thermo Fisher S
October 25, 2023	EX-99.1	Excerpt from transcript of Q3 2023 Earnings Call held on October 25, 2023. Exhibit 99.1 The following is an excerpt from the transcript of Thermo Fisher’s Q3 2023 earnings call held on October 25, 2023: Shortly after the close of the quarter we announced the agreement to acquire Olink, a company that is accelerating proteomics. Olink’s products enable leading academic researchers and the biopharmaceutical companies to gain an understanding of disease at the protein level
October 17, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 THERMO FISHER SC false000009774500000977452023-10-172023-10-170000097745us-gaap:CommonStockMember2023-10-172023-10-170000097745tmo:Zero875NotesDue2031Member2023-10-172023-10-170000097745tmo:Zero125NotesDue2025Member2023-10-172023-10-170000097745tmo:One500NotesDue2039Member2023-10-172023-10-170000097745tmo:Three650NotesDue2034Member2023-10-172023-10-170000097745tmo:Zero750NotesDue2024Member2023-10-172023-10-1700000
October 17, 2023	EX-99.4	Letter to Partners / Suppliers Exhibit 99.4 TMO – OLK Partner / Supplier Letter October 17, 2023 Dear Valued Partner: As an important partner to Thermo Fisher, I am pleased to share that we recently announced an agreement to acquire Olink, a leading provider of next generation proteomics solutions. This announcement marks an exciting milestone for Thermo Fisher and furthers our commitment to serving science as we fulfill our Mi
October 17, 2023	EX-99.1	Letter to Employees from Chairman, President and Chief Executive Officer Exhibit 99.1 TMO – OLK Marc Email to All TMO Employees Marc N. Casper Chairman, President and Chief Executive Officer October 17, 2023 Dear Colleague: I am very pleased to share that Thermo Fisher has announced an agreement to acquire Olink, a company dedicated to accelerating proteomics. Olink is headquartered in Sweden with global operations and has approximately 600 employees. It offers leading
October 17, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) American Depositary Shares, each representing one Common Share, quota value SEK 2.
October 17, 2023	EX-99.5	Letter to Customers Exhibit 99.5 TMO – OLK Customer Letter October 17, 2023 Dear Valued Customer: As an important Thermo Fisher customer, I am pleased to share that we recently announced an agreement to acquire Olink, a leading provider of next generation proteomics solutions. This announcement marks an exciting milestone for Thermo Fisher and furthers our commitment to serving science as we fulfill our Mission – ena
October 17, 2023	EX-99.3	Corporate Social Media Posts Exhibit 99.3 The following communication was posted by Thermo Fisher Scientific, Inc. (the “Company”) on X (formerly Twitter) on October 17, 2023. We are excited to announce that we have entered into an agreement to acquire @OlinkProteomics, a leading provider of next generation proteomics solutions. We look forward to welcoming their team to Thermo Fisher. Learn more in our Press Release: [Link t
October 17, 2023	EX-99.1	Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and M Exhibit 99.1 Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and Mass Spectrometry Offerings, Accelerating Protein Biomarker Discovery and Providing Strong Synergy Opportunities WALTHAM, Mass. and UPPSAL
October 17, 2023	EX-99.1	Press Release, dated October 17, 2023. Exhibit 99.1 Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and Mass Spectrometry Offerings, Accelerating Protein Biomarker Discovery and Providing Strong Synergy Opportunities WALTHAM, Mass. and UPPSAL
October 17, 2023	EX-99.2	Letter to Employees from Executive Vice President Exhibit 99.2 TMO – OLK LSG Letter from Gianluca Gianluca Pettiti Executive Vice President October 17, 2023 Dear Colleague: I’m reaching out regarding the exciting announcement that Thermo Fisher made today about entering into an agreement to acquire Olink, a leading provider of next generation proteomics solutions. By now, you should have received an email from Marc Casper highlighting some of the
October 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 THERMO FISHER SC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 001-08002 04-2209186 (State of incorporation) (Commission File Number) (
September 21, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 THERMO FISHER SCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.
August 10, 2023	EX-4.2	Twenty-Seventh Supplemental Indenture, dated as of August 10, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee Exhibit 4.2 EXECUTION VERSION THERMO FISHER SCIENTIFIC INC., as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee TWENTY-SEVENTH SUPPLEMENTAL INDENTURE Dated as of August 10, 2023 4.953% Senior Notes due 2026 4.977% Senior Notes due 2030 5.086% Senior Notes due 2033 5.404% Senior Notes due 2043 THIS TWENTY-SEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) is dated
August 10, 2023	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commiss
August 10, 2023	EX-1.1	THERMO FISHER SCIENTIFIC INC. 4.953% Senior Notes due 2026 4.977% Senior Notes due 2030 5.086% Senior Notes due 2033 5.404% Senior Notes due 2043 UNDERWRITING AGREEMENT August 7, 2023 BNP Paribas Securities Corp. Citigroup Global Markets Inc. Goldman Exhibit 1.1 Execution Copy THERMO FISHER SCIENTIFIC INC. $600,000,000 4.953% Senior Notes due 2026 $750,000,000 4.977% Senior Notes due 2030 $1,000,000,000 5.086% Senior Notes due 2033 $600,000,000 5.404% Senior Notes due 2043 UNDERWRITING AGREEMENT August 7, 2023 BNP Paribas Securities Corp. Citigroup Global Markets Inc. Goldman Sachs & Co. LLC Mizuho Securities USA LLC BNP PARIBAS SECURITIES COR
August 8, 2023	424B5	Thermo Fisher Scientific Inc. $600,000,000 4.953% Senior Notes due 2026 $750,000,000 4.977% Senior Notes due 2030 $1,000,000,000 5.086% Senior Notes due 2033 $600,000,000 5.404% Senior Notes due 2043 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-263034 PROSPECTUS SUPPLEMENT (To prospectus dated February 25, 2022) $2,950,000,000 Thermo Fisher Scientific Inc. $600,000,000 4.953% Senior Notes due 2026 $750,000,000 4.977% Senior Notes due 2030 $1,000,000,000 5.086% Senior Notes due 2033 $600,000,000 5.404% Senior Notes due 2043 We are offering $600,000,000 aggregate principal a
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 THERMO FISHER SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commissi
August 8, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: THERMO FISHER SCIENTIFIC INC.
August 7, 2023	FWP	Thermo Fisher Scientific Inc. $600,000,000 4.953% Senior Notes due 2026 (the “2026 Notes”) $750,000,000 4.977% Senior Notes due 2030 (the “2030 Notes”) $1,000,000,000 5.086% Senior Notes due 2033 (the “2033 Notes”) $600,000,000 5.404% Senior Notes du Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-263034 Thermo Fisher Scientific Inc. $600,000,000 4.953% Senior Notes due 2026 (the “2026 Notes”) $750,000,000 4.977% Senior Notes due 2030 (the “2030 Notes”) $1,000,000,000 5.086% Senior Notes due 2033 (the “2033 Notes”) $600,000,000 5.404% Senior Notes due 2043 (the “2043 Notes”) August 7, 2023 Pricing Term Sheet Issu
August 7, 2023	424B5	Subject to Completion, dated August 7, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
August 4, 2023	EX-10.1	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement for Directors Exhibit 10.1 THERMO FISHER SCIENTIFIC INC. RESTRICTED STOCK UNIT AGREEMENT Granted Under the Amended and Restated 2013 Stock Incentive Plan 1.Award of Restricted Stock Units. This agreement (the “Agreement”) sets forth the terms and conditions of an award by Thermo Fisher Scientific Inc., a Delaware corporation, on , 202 (the “Award Date”) to (the “Participant”) of restricted stock units of the Co
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 1, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as s
July 26, 2023	EX-99.1	Thermo Fisher Scientific Reports Second Quarter 2023 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Second Quarter 2023 Results WALTHAM, Mass. (July 26, 2023) – Thermo Fisher Sci
July 26, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S.
July 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 THERMO FISHER SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S.
June 21, 2023	11-K	-K for the fiscal year ended December 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (mark one) [ X ] Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2022 [ ] Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC.
May 30, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 (State or other jurisdiction of incorpo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 (State or other jurisdiction of incorporation or organization) (Commission File Number) 168 Third Avenue Waltham, MA 02451 (Address of principal executive offices) (Zip Code) Michael A. Box
May 30, 2023	EX-1.01	Exhibit 1.01 Exhibit 1.01 Conflict Minerals Report I. INTRODUCTION Thermo Fisher Scientific Inc. (“Thermo Fisher,” the “Company,” “we,” “us” or “our”) has included this Conflict Minerals Report (the “Report”) as an exhibit to its Form SD, as provided in Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1” or the “Conflict Minerals Rule”) for the reporting period from January 1, 2022 to December 3
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 THERMO FISHER SCIENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S.
May 24, 2023	EX-99.1	Thermo Fisher Scientific Inc. Amended and Restated 2013 Stock Incentive Plan THERMO FISHER SCIENTIFIC INC. AMENDED AND RESTATED 2013 STOCK INCENTIVE PLAN 1.Purpose. The purpose of this Amended and Restated 2013 Stock Incentive Plan, as may be further amended from time to time (the “Plan”), of Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain
May 24, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 6 exhibit107.htm EXHIBIT 107 Exhibit 107 Calculation of filing Fee Tables Form S-8 (Form Type) Thermo Fisher Scientific Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate
May 24, 2023	EX-99.2	Thermo Fisher Scientific Inc. 2023 Global Employee Stock Purchase Plan THERMO FISHER SCIENTIFIC INC. 2023 GLOBAL EMPLOYEE STOCK PURCHASE PLAN 1.Purpose of the Plan. The purpose of the Thermo Fisher Scientific Inc. 2023 Global Employee Stock Purchase Plan, as may be amended from time to time (the “Plan”), is to provide Eligible Employees of Thermo Fisher Scientific Inc., a Delaware corporation (or any successor corporation) (the “Company”) and its subsidiaries and aff
May 24, 2023	S-8	As filed with the Securities and Exchange Commission on May 24, 2023 As filed with the Securities and Exchange Commission on May 24, 2023 Registration No.
May 5, 2023	EX-10.7	Form of Executive Change in Control Retention Agreement for Officers (other than Marc N. Casper) Exhibit 10.7 EXECUTIVE CHANGE IN CONTROL RETENTION AGREEMENT THIS AGREEMENT by and between THERMO FISHER SCIENTIFIC INC., a Delaware corporation (the “Company”), and (the “Executive”) is made as of , 2023 (the “Effective Date”). WHEREAS, the Company recognizes that, as is the case with many publicly-held corporations, the possibility of a change in control of the Company exists and that such possi
May 5, 2023	EX-10.6	Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 22, 2023 Exhibit 10.6 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Marc N. Casper Grant date (“Grant Date”): Numbe
May 5, 2023	EX-10.4	Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper Exhibit 10.4 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Marc N. Casper Award date
May 5, 2023	EX-10.3	Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement effective as of February 22, 2023 Exhibit 10.3 THERMO FISHER SCIENTIFIC INC. NONSTATUTORY STOCK OPTION AGREEMENT This Nonstatutory Stock Option Agreement (this “Agreement”) is made as of the Grant Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Grant Name of participant (the “Participant”): Grant date (“Grant Date”): Number of shares of
May 5, 2023	EX-10.2	Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement Exhibit 10.2 THERMO FISHER SCIENTIFIC INC. RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Award date (“Award Date”): Number of shares of the Compa
May 5, 2023	EX-10.1	Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement Exhibit 10.1 THERMO FISHER SCIENTIFIC INC. PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Award date (“Award Date”):
May 5, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 1, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as
May 5, 2023	EX-10.5	Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper Exhibit 10.5 THERMO FISHER SCIENTIFIC INC. RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below. Notice of Award Name of participant (the “Participant”): Marc N. Casper Award date (“Award Date”): Number of shar
April 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 THERMO FISHER SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S
April 26, 2023	EX-99.1	Thermo Fisher Scientific Reports First Quarter 2023 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports First Quarter 2023 Results WALTHAM, Mass. (April 26, 2023) – Thermo Fisher Sci
April 7, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__ ) þ Filed by the Registrant ¨ Filed by a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted b
April 7, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__ ) þ Filed by the Registrant ¨ Filed by a Party other UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6
April 7, 2023	DEF 14A	COURTESY PDF OF PROXY STATEMENT Notice of Annual Meeting of Shareholders and Proxy Statement 2023 Our Mission is to enable our customers to make the world healthier, cleaner and safer brighter future Building aOur Mission is to enable our customers to make the world healthier, cleaner and safer.
February 23, 2023	EX-22	Subsidiary Issuer of Guaranteed Securities Exhibit 22 Subsidiary Issuer of Guaranteed Securities Thermo Fisher Scientific Inc.
February 23, 2023	EX-3.4	Amended and Restated By-Laws of the Registrant, as amended and effective as of February 22, 2023 Exhibit 3.4 As amended and restated effective as of February 22, 2023 Thermo Fisher Scientific Inc. BY-LAWS TABLE OF CONTENTS Title Page ARTICLE I - STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Notice of Meetings 3 Section 4. Quorum; Adjournments 4 Section 5. Voting; Proxies 4 Section 6. Inspectors of Elections 5 Section 7. Presiding Officer and Secretary 5 S
February 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as spec
February 23, 2023	EX-10.45	Amendment to Nonstatutory Stock Option Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper Exhibit 10.45 THERMO FISHER SCIENTIFIC INC. AMENDMENT TO NONSTATUTORY STOCK OPTION AGREEMENTS Granted under 2013 Stock Incentive Plan 1.Reference is made to the letter agreement (the “Letter Agreement”) dated as of November 10, 2022 between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) providing for the addition of retirement vesting provisions to certain of th
February 23, 2023	EX-4.19	Description of the Registrant’s Securities Exhibit 4.19 Description of Registrant’s Securities The following description of registered securities of Thermo Fisher Scientific Inc. is intended as a summary only and therefore is not a complete description. As used in this “Description of Registrant’s Securities,” the terms “Thermo Fisher,” “Company,” “we,” “our” and “us” refer to Thermo Fisher Scientific Inc. and do not, unless the context ot
February 23, 2023	EX-10.46	Amendment to Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper Exhibit 10.46 THERMO FISHER SCIENTIFIC INC. AMENDMENT TO RESTRICTED STOCK UNIT AGREEMENTS Granted under 2013 Stock Incentive Plan 1.Reference is made to the letter agreement (the “Letter Agreement”) dated as of November 10, 2022 between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) providing for the addition of retirement vesting provisions to certain of the Ex
February 23, 2023	EX-10.47	Amendment to Performance Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper Exhibit 10.47 THERMO FISHER SCIENTIFIC INC. AMENDMENT TO PERFORMANCE RESTRICTED STOCK UNIT AGREEMENTS Granted under 2013 Stock Incentive Plan 1.Reference is made to the letter agreement (the “Letter Agreement”) dated as of November 10, 2022 between Thermo Fisher Scientific Inc. (the “Company”) and Marc N. Casper (the “Executive”) providing for the addition of retirement vesting provisions to certa
February 23, 2023	EX-21	Subsidiaries of the Registrant Exhibit 21 THERMO FISHER SCIENTIFIC INC. NAME STATE OR JURISDICTION OF ORGANIZATION PERCENT OF OWNERSHIP Thermo Fisher Scientific Operating Company LLC Delaware 100 Thermo Fisher Scientific Senior Financing LLC Delaware 100 Thermo Fisher Scientific (DE) Holding S.a.r.l. Luxembourg 100 Laboratory Management Systems, Inc. Delaware 100 Thermo Fisher Scientific Peru S.R.L. [1% by Fisher Clinical Servi
February 9, 2023	SC 13G/A	TMO / Thermo Fisher Scientific Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02038-thermofisherscientif.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Thermo Fisher Scientific Inc. Title of Class of Securities: Common Stock CUSIP Number: 883556102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate
February 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R
February 1, 2023	EX-99.1	Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results WALTHAM, Mass. (February 1, 2023) –
November 21, 2022	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 8-A12B 1 ny20005859x88a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Thermo Fisher Scientific Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization)
November 21, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commi
November 21, 2022	EX-1.2	THERMO FISHER SCIENTIFIC INC. $600,000,000 4.800% Senior Notes due 2027 $600,000,000 4.950% Senior Notes due 2032 UNDERWRITING AGREEMENT November 14, 2022 BofA Securities, Inc. Citigroup Global Markets Inc. Deutsche Bank Securities Inc. EX-1.2 3 ny20005859x7ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 EXECUTION COPY THERMO FISHER SCIENTIFIC INC. $600,000,000 4.800% Senior Notes due 2027 $600,000,000 4.950% Senior Notes due 2032 UNDERWRITING AGREEMENT November 14, 2022 BofA Securities, Inc. Citigroup Global Markets Inc. Deutsche Bank Securities Inc. BofA Securities, Inc. Citigroup Global Markets Inc. Deutsche Bank SECURITIes Inc. As Represen
November 21, 2022	EX-4.2	Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee Exhibit 4.2 EXECUTION COPY THERMO FISHER SCIENTIFIC INC., as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee TWENTY-FIFTH SUPPLEMENTAL INDENTURE Dated as of November 21, 2022 3.200% Senior Notes due 2026 3.650% Senior Notes due 2034 THIS TWENTY-FIFTH SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?) is dated as of November 21, 2022 between THERMO FISHER SCIENTIFIC INC.,
November 21, 2022	EX-1.1	THERMO FISHER SCIENTIFIC INC. 3.200% Senior Notes due 2026 3.650% Senior Notes due 2034 UNDERWRITING AGREEMENT November 14, 2022 Citigroup Global Markets Limited Deutsche Bank AG, London Branch Merrill Lynch International EX-1.1 2 ny20005859x7ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION COPY THERMO FISHER SCIENTIFIC INC. €500,000,000 3.200% Senior Notes due 2026 €750,000,000 3.650% Senior Notes due 2034 UNDERWRITING AGREEMENT November 14, 2022 Citigroup Global Markets Limited Deutsche Bank AG, London Branch Merrill Lynch International CITIGROUP GLOBAL MARKETS LIMITED DEUTSCHE BANK AG, LONDON BRANCH MERRILL LYNCH INT
November 21, 2022	EX-4.3	Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee Exhibit 4.3 EXECUTION COPY THERMO FISHER SCIENTIFIC INC., as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee TWENTY-SIXTH SUPPLEMENTAL INDENTURE Dated as of November 21, 2022 4.800% Senior Notes due 2027 4.950% Senior Notes due 2032 THIS TWENTY-SIXTH SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?) is dated as of November 21, 2022 between THERMO FISHER SCIENTIFIC INC.,
November 15, 2022	424B5	Thermo Fisher Scientific Inc. $600,000,000 4.800% Senior Notes due 2027 $600,000,000 4.950% Senior Notes due 2032 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-263034 PROSPECTUS SUPPLEMENT (To prospectus dated February 25, 2022) $1,200,000,000 ? Thermo Fisher Scientific Inc. $600,000,000 4.800% Senior Notes due 2027 $600,000,000 4.950% Senior Notes due 2032 We are offering $600,000,000 aggregate principal amount of 4.800% Senior Notes due 2027 (the ?2027 notes?) and $600,000,000 aggregate pr
November 15, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: THERMO FISHER SCIENTIFIC INC.
November 15, 2022	424B5	Thermo Fisher Scientific Inc. €500,000,000 3.200% Senior Notes due 2026 €750,000,000 3.650% Senior Notes due 2034 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-263034 PROSPECTUS SUPPLEMENT (To prospectus dated February 25, 2022) ?1,250,000,000 ? Thermo Fisher Scientific Inc. ?500,000,000 3.200% Senior Notes due 2026 ?750,000,000 3.650% Senior Notes due 2034 We are offering ?500,000,000 aggregate principal amount of 3.200% Senior Notes due 2026 (the ?2026 notes?) and ?750,000,000 aggregate pr
November 15, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: THERMO FISHER SCIENTIFIC INC.
November 14, 2022	424B5	Subject to Completion, dated November 14, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
November 14, 2022	FWP	Thermo Fisher Scientific Inc. $600,000,000 4.800% Senior Notes due 2027 (the “2027 Notes”) $600,000,000 4.950% Senior Notes due 2032 (the “2032 Notes”) November 14, 2022 Pricing Term Sheet Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-263034 Thermo Fisher Scientific Inc. $600,000,000 4.800% Senior Notes due 2027 (the ?2027 Notes?) $600,000,000 4.950% Senior Notes due 2032 (the ?2032 Notes?) November 14, 2022 Pricing Term Sheet Issuer: Thermo Fisher Scientific Inc. Securities: 4.800% Senior Notes due 2027 4.950% Senior Notes due 2032 Expected Ratings
November 14, 2022	FWP	Thermo Fisher Scientific Inc. €500,000,000 3.200% Senior Notes due 2026 (“2026 Notes”) €750,000,000 3.650% Senior Notes due 2034 (“2034 Notes”) November 14, 2022 Pricing Term Sheet Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
November 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.
November 14, 2022	424B5	Subject to Completion, dated November 14, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
November 14, 2022	EX-10.1	Letter Agreement by and between Marc N. Casper and Thermo Fisher Scientific Inc., dated as of November 10, 2022 Exhibit 10.1 November 10, 2022 Marc N. Casper c/o Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451 Dear Marc, This letter relates to your outstanding stock options (originally granted between 2017 and 2022) and your outstanding time-based and performance-based restricted stock units (originally granted between 2020 and 2022). The purpose of this letter is to memorialize
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended October 1, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant a
October 26, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R
October 26, 2022	EX-99.1	Thermo Fisher Scientific Reports Third Quarter 2022 Results Exhibit 99.1 News FOR IMMEDIATE DISTRIBUTION Media Contact: Sandy Pound Investor Contact: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Third Quarter 2022 Results WALTHAM, Mass. (October 26, 2022) ? Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, toda
October 20, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State or other jurisdiction of incorporation) (Commis
October 20, 2022	EX-1.1	THERMO FISHER SCIENTIFIC INC. ¥22,300,000,000 0.853% Senior Notes due 2025 ¥28,900,000,000 1.054% Senior Notes due 2027 ¥4,700,000,000 1.279% Senior Notes due 2029 ¥6,300,000,000 1.490% Senior Notes due 2032 ¥14,600,000,000 2.069% Senior Notes due 20 Exhibit 1.1 THERMO FISHER SCIENTIFIC INC. ?22,300,000,000 0.853% Senior Notes due 2025 ?28,900,000,000 1.054% Senior Notes due 2027 ?4,700,000,000 1.279% Senior Notes due 2029 ?6,300,000,000 1.490% Senior Notes due 2032 ?14,600,000,000 2.069% Senior Notes due 2042 ?33,300,000,000 2.382% Senior Notes due 2052 UNDERWRITING AGREEMENT October 14, 2022 Citigroup Global Markets Limited Mizuho Securities
October 20, 2022	EX-4.2	Twenty-Fourth Supplemental Indenture, dated as of October 20, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee Exhibit 4.2 THERMO FISHER SCIENTIFIC INC., as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee TWENTY-FOURTH SUPPLEMENTAL INDENTURE Dated as of October 20, 2022 0.853% Senior Notes due 2025 1.054% Senior Notes due 2027 1.279% Senior Notes due 2029 1.490% Senior Notes due 2032 2.069% Senior Notes due 2042 2.382% Senior Notes due 2052 THIS TWENTY-FOURTH SUPPLEMENTAL INDENTURE (
October 14, 2022	424B5	Thermo Fisher Scientific Inc. ¥22,300,000,000 0.853% Senior Notes due 2025 ¥28,900,000,000 1.054% Senior Notes due 2027 ¥4,700,000,000 1.279% Senior Notes due 2029 ¥6,300,000,000 1.490% Senior Notes due 2032 ¥14,600,000,000 2.069% Senior Notes due 20 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-263034 PROSPECTUS SUPPLEMENT (To prospectus dated February 25, 2022) ?110,100,000,000 ? Thermo Fisher Scientific Inc. ?22,300,000,000 0.853% Senior Notes due 2025 ?28,900,000,000 1.054% Senior Notes due 2027 ?4,700,000,000 1.279% Senior Notes due 2029 ?6,300,000,000 1.490% Senior Notes due 2032 ?14,600,000,000 2.069% Senior Notes due
October 14, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: THERMO FISHER SCIENTIFIC INC.
October 14, 2022	FWP	Thermo Fisher Scientific Inc. Term Sheet October 14, 2022 0.853% Senior Notes due 2025 1.054% Senior Notes due 2027 1.279% Senior Notes due 2029 1.490% Senior Notes due 2032 2.069% Senior Notes due 2042 2.382% Senior Notes due 2052 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.
October 11, 2022	424B5	Subject to Completion, dated October 11, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
October 6, 2022	CORRESP	2 Thermo Fisher Scientific 168 Third Avenue Waltham, MA 02451 www.thermofisher.com VIA EDGAR October 6, 2022 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Lynn Dicker and Kristin Lochhead Division of Corporation Finance Office of Life Sciences Re: Response to Comment Letter dated September 22, 2022 Thermo Fisher Scientific Inc.
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended July 2, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified
July 28, 2022	EX-99.1	Thermo Fisher Scientific Reports Second Quarter 2022 Results Exhibit 99.1 News FOR IMMEDIATE DISTRIBUTION Media Contact Information: Ron O'Brien Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1242 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports Second Quarter 2022 Results WALTHAM, Mass. (July 28, 2022) ? Thermo Fisher
July 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S.
June 16, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (mark one) [ X ] Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2021 [ ] Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC.
May 27, 2022	EX-1.01	Exhibit 1.01 Exhibit 1.01 Conflict Minerals Report I. INTRODUCTION This Conflict Minerals Report (the ?Report?) for Thermo Fisher Scientific Inc. (?Thermo Fisher,? the ?Company,? ?we,? or ?our?) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (?Rule 13p-1?) for the reporting period from January 1, 2021 to December 31, 2021. Rule 13p-1 is applicable to SEC issuers that manufa
May 27, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 (State or other jurisdiction of incorpo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT THERMO FISHER SCIENTIFIC INC. (Exact name of registrant as specified in its charter) Delaware 1-8002 (State or other jurisdiction of incorporation or organization) (Commission File Number) 168 Third Avenue Waltham, MA 02451 (Address of principal executive offices) (Zip Code) Michael A. Box
May 19, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S.
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended April 2, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified
April 28, 2022	EX-99.1	Thermo Fisher Scientific Reports First Quarter 2022 Results Exhibit 99.1 News FOR IMMEDIATE RELEASE Media Contact Information: Ron O'Brien Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1242 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Reports First Quarter 2022 Results WALTHAM, Mass. (April 28, 2022) ? Thermo Fisher Scie
April 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter) Delaware 1-8002 04-2209186 (State of incorporation) (Commission File Number) (I.R.S
April 7, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__ ) þ Filed by the Registrant ¨ Filed by a Party other UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6
April 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__ ) þ Filed by the Registrant ¨ Filed by a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted b
February 25, 2022	EX-25.1	The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of The Bank of New York Mellon Trust Company, N.A. with respect to the Thermo Fisher Senior Indenture dated as of November 20, 2009 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trustee as specified in its charter) (Ju

DE:TN8	€ 419.10
PE:TMO
MX:TMO
GB:0R0H	US$ 498.83
IT:1TMO	€ 419.80
AT:TMOF

TMO / Thermo Fisher Scientific Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings